Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Polar Capital Global Healthcare Trust plc (PGHZ) ZDP

Sell:105.00p Buy:110.00p 0 Change: No change
Market closed Prices as at close on 21 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:105.00p
Buy:110.00p
Change: No change
Market closed Prices as at close on 21 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:105.00p
Buy:110.00p
Change: No change
Market closed Prices as at close on 21 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks across all four healthcare sub-sectors, being pharmaceuticals, biotechnology, medical technology and healthcare services.
Security Weight
Becton, Dickinson and Co 4.99%
Medtronic plc Common Stock USD0.0001 4.70%
Amgen Inc 4.66%
Roche Holdings AG NPV 4.64%
Fresenius Medical Care AG & Co.Kgaa NPV 4.39%
Avantor Inc 3.62%
Sanofi Ordinary Euro 2 3.56%
Koninklijke Philips NV Euro.20 3.39%
Syneos Health Inc A 3.19%
Horizon Therapeutics plc Ordinary Shares 3.12%
Sector Weight
Healthcare 102.73%
Basic Materials 3.62%
Financial Services 0.63%
Country Weight
United States 75.82%
Germany 7.45%
Netherlands 6.20%
Denmark 5.66%
Switzerland 4.64%
France 3.56%
United Kingdom 2.14%
Japan 1.51%

Fee Structure

Dividend Policy

Dividends will be paid bi-annually in February and August.

ASSET SPLIT

Total number of holdings: 45.

Trust Manager

James Douglas

Manager Bio

James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management.

Board Of Directors

Jeremy Whitley, Lisa Arnold, Andrew Fleming, Neal Ransome

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.